Literature DB >> 29238923

Endoscopic therapy and curative effect in pituitary adenoma patients complicated by acromegalic cardiomyopathy.

Heping Zhou1,2, Zhengjiang Zha3, Xiangdong Li4, Xinsheng Chen2, Jing Wang5, Zhongzhou Su6.   

Abstract

The study aimed to retrospectively analyze the clinical characteristics of patients with pituitary adenomas complicated by acromegalic cardiomyopathy and to evaluate the effect of endoscopic surgery. Eighty-six pituitary adenoma patients complicated by acromegalic cardiomyopathy who were treated with endoscopic surgery in the First Affiliated Hospital of Soochow University from January 2010 to December 2016 were enrolled. We noted patient clinical characteristics and explored the relationships with surgical treatment. Before and after surgery, all patients underwent an examination of pituitary endocrinology, brain magnetic resonance (MR), and echocardiography. The serum levels of growth hormone (GH), left ventricular end-diastolic diameter (LVIDd), interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), left ventricular ejection fraction (EF), and mitral valve (E/A ratio) were examined with non-invasive methods, and the results were compared. Of the 86 patients, there were 23 with microadenomas, 27 with large adenomas, and 36 with giant adenomas. There were 28 patients with invasive adenomas and 58 with non-invasive adenomas. The pre-operative mean GH level was 71.23 ± 3.29 μg/L, which was positively correlated with tumor volume (r = 0.751, P < 0.01). Via trans-sphenoidal endoscopic pituitary adenoma resection, 51 patients underwent total tumor resections, 25 underwent subtotal resections, 8 underwent major part resections, and 2 underwent partial resections. After surgery, the GH mean level was 3.81 ± 1.03 μg/L, which was significantly different (t = 3.72, P < 0.01) from the pre-operative level. Cardiac function indices, including LVIDd, IVST, LVPWT, E/A, and EF, were significantly improved. The long-term curative rate was 39.17% and the remission rate was 77.29%. For pituitary adenoma patients complicated by acromegalic cardiomyopathy, endoscopic surgery resulted in a good curative effect and the growth hormone levels were maintained, which can significantly improve cardiac structure and function.

Entities:  

Keywords:  Acromegalic cardiomyopathy; Endoscopic surgery; Growth hormone; Pituitary adenoma

Mesh:

Substances:

Year:  2017        PMID: 29238923     DOI: 10.1007/s10143-017-0936-7

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  19 in total

Review 1.  Management of clinically non-functioning pituitary adenoma.

Authors:  Philippe Chanson; Gerald Raverot; Frédéric Castinetti; Christine Cortet-Rudelli; Françoise Galland; Sylvie Salenave
Journal:  Ann Endocrinol (Paris)       Date:  2015-06-10       Impact factor: 2.478

2.  Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.

Authors:  Lucia Schwyzer; Robert M Starke; John A Jane; Edward H Oldfield
Journal:  J Neurosurg       Date:  2014-11-28       Impact factor: 5.115

Review 3.  Pituitary macroadenoma causing symptomatic internal carotid artery compression: surgical treatment through transsphenoidal tumor resection.

Authors:  Roberto Rey-Dios; Troy D Payner; Aaron A Cohen-Gadol
Journal:  J Clin Neurosci       Date:  2013-08-23       Impact factor: 1.961

Review 4.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

5.  Negative regulation of human growth hormone gene expression by insulin is dependent on hypoxia-inducible factor binding in primary non-tumor pituitary cells.

Authors:  Hana Vakili; Yan Jin; Peter A Cattini
Journal:  J Biol Chem       Date:  2012-07-25       Impact factor: 5.157

Review 6.  Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications.

Authors:  John J Kopchick; Edward O List; Bruce Kelder; Elahu S Gosney; Darlene E Berryman
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

Review 7.  Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

Review 8.  Medical management of functioning pituitary adenoma: an update.

Authors:  Yutaka Oki
Journal:  Neurol Med Chir (Tokyo)       Date:  2014-11-29       Impact factor: 1.742

9.  The association between biochemical control and cardiovascular risk factors in acromegaly.

Authors:  John D Carmichael; Michael S Broder; Dasha Cherepanov; Eunice Chang; Adam Mamelak; Qayyim Said; Maureen P Neary; Vivien Bonert
Journal:  BMC Endocr Disord       Date:  2017-03-09       Impact factor: 2.763

10.  Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.

Authors:  N C van Varsseveld; C C van Bunderen; A A M Franken; H P F Koppeschaar; A J van der Lely; M L Drent
Journal:  Pituitary       Date:  2016-08       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.